CHAPTER 1 INTRODUCTION
1.1 Report Description
1.2 Key Market Benefits
1.3 Key Market Segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top impacting factors
3.2.2 Top investment pockets
3.2.3 Top winning strategies
3.3 Government Regulations
3.4 Reimbursement Scenario
3.5 Porters Five Force Analysis
3.5.1 Complex and highly differentiated nature of raw materials increases bargaining power of suppliers
3.5.2 Fewer manufacturers of anti-inflammatory drugs limits the bargaining power of buyers
3.5.3 High capital investment and patent provision lowers the threats from new entrants
3.5.4 Difficulty to imitate the original biologics lowers the threat of substitutes
3.5.5 Industry rivalry is low to moderate due to presence of few competitors
3.6 Value chain analysis
3.7 Clinical Trials
3.8 Patent Analysis
3.9 Market Share Analysis, (2014)
3.10 Market dynamics
3.10.1 Drivers
3.10.1.1 Rising incidences of autoimmune and respiratory conditions:
3.10.1.2 New Drugs in Pipeline
3.10.1.3 Increasing adoption rate of anti-inflammatory drugs
3.10.2 Restraints
3.10.2.1 Side Effects of Anti-Inflammatory Drugs
3.10.2.2 Patent expirations
3.10.3 Opportunities
3.10.3.1 Developing biosimilars for the existing drugs
3.10.3.2 Tapping the emerging markets in developing regions
CHAPTER 4 BY INDICATION
4.1 Arthritis
4.1.1 Market size and forecast
4.1.2 Rheumatoid Arthritis
4.1.3 Osteoarthritis
4.1.4 Ankylosing Spondylitis
4.1.5 Psoriatic Arthritis
4.1.6 Gout
4.2 Respiratory Diseases
4.2.1 Market size and forecast
4.2.2 Asthma
4.2.3 Chronic obstructive pulmonary disease (COPD)
4.3 Multiple Sclerosis
4.3.1 Market size and forecast by region
4.4 Psoriasis
4.4.1 Market size and forecast
4.5 Inflammatory Bowel Disease (IBD)
4.5.1 Market size and forecast
4.5.2 Crohns Disease
4.5.3 Ulcerative Colitis
4.6 Other Inflammatory Diseases
4.6.1 Market size and forecast
CHAPTER 5 BY DRUG CLASS
5.1 Anti-inflammatory Biologics
5.1.1 Key Market Trends
5.1.2 Market Growth factors and opportunities
5.1.3 Market size and forecast
5.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.2.1 Key Market Trends
5.2.2 Market growth factors and opportunities
5.2.3 Market size and forecast
5.3 Corticosteroids
5.3.1 Key Market Trends
5.3.2 Market Growth factors and opportunities
5.3.3 Market size and forecast
5.4 Other anti-inflammatory drugs
CHAPTER 6 BY COUNTRY
6.1 Key market trends
6.2 Key growth factors and opportunities
6.2.1 Market size and forecast
6.3 Japan
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.4 China
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.5 India
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.6 Australia
6.6.1 Key market trends
6.6.2 Key growth factors and opportunities
6.6.3 Market size and forecast
6.7 South Korea
6.7.1 Key market trends
6.7.2 Key growth factors and opportunities
6.7.3 Market size and forecast
6.8 Indonesia
6.8.1 Key market trends
6.8.2 Key growth factors and opportunities
6.8.3 Market size and forecast
6.9 Rest of Asia Pacific
CHAPTER 7 COMPANY PROFILES
7.1 Pfizer Inc.
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Business performance
7.1.4 Strategic moves and developments
7.1.5 SWOT analysis & strategic conclusions
7.2 AbbVie Inc.
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Business performance
7.2.4 Strategic Moves and Developments
7.2.5 SWOT analysis & strategic conclusions
7.3 Johnson & Johnson
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Business performance
7.3.4 Strategic Moves and Developments
7.3.5 SWOT analysis & strategic conclusions
7.4 GlaxoSmithKline plc
7.4.1 Company Overview
7.4.2 Company snapshot
7.4.3 Business performance:
7.4.4 Strategic moves and developments
7.4.5 SWOT analysis & strategic conclusions
7.5 Merck & Co., Inc.
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Business Performance
7.5.4 Strategic Moves and Developments
7.5.5 SWOT analysis and strategic conclusions
7.6 Novartis AG
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Business Performance
7.6.4 Strategic moves and developments
7.6.5 SWOT analysis and strategic conclusions
7.7 F. Hoffmann-La Roche AG
7.7.1 Company profile
7.7.2 Company snapshot
7.7.3 Business Performance
7.7.4 Strategic moves and developments
7.7.5 SWOT analysis and strategic conclusions
7.8 Eli Lily and Company
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Business performance
7.8.4 Strategic Moves and Developments
7.8.5 SWOT analysis and strategic conclusions
7.9 AstraZeneca PLC.
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Business performance
7.9.4 Strategic Moves and Developments
7.9.5 SWOT analysis and strategic conclusions
7.10 Amgen Inc.
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Business performance
7.10.4 Strategic Moves and Developments
7.10.5 SWOT analysis and strategic conclusions
